ClinicalTrials.gg
CompletedNCT03580018Updated Jul 12, 2018

Intraarticular Injection of Tranexamic Acid Reduced Postoperative Hemarthrosis in Arthroscopic Anterior Cruciate Ligament Reconstruction

An interventional study of Tranexamic Acid Powder and Post-anterior cruciate ligament reconstruction (ACLR) in Anterior Cruciate Ligament Reconstruction, sponsored by Taipei Veterans General Hospital, Taiwan. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by Taipei Veterans General Hospital, Taiwan · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jun 2017, registered Jun 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Post-anterior cruciate ligament reconstruction (ACLR) hemarthrosis may result in increased pain thus delaying postoperative rehabilitation, which may eventually lead to arthrofibrosis and a functional deficit. Many antifibrinolytic agents, including tranexamic acid (TXA), have been used in orthopedic surgeries to reduce postoperative bleeding.The purpose of this study is to evaluate the effect of intra-articular injection of TXA in patients receiving arthroscopic ACLRs. Patients were randomized into two groups. Group 1 patients (TXA group) received the index procedures with a 10 mL intra-articular injection of TXA. Group 2 (control group) patients received the index procedures without TXA injections. An intra-articular suction drain was placed recorded 24 h postoperatively. Clinical evaluations using an IKDC functional score, range of motion (ROM), and a Visual Analogue Scale (VAS) pain score were performed at postoperative day 3 and week 4.

Read the detailed description

TXA group patients received ACLRs and a 10 mL intra-articular injection of TXA after the procedure. The control group patients only received ACLRs without TXA injections. Randomization was done on the day of the surgery, by an independent investigator who did not participate in the surgery, using the permuted block randomization technique.

The same surgeon treated all patients enrolled in this study. Spinal anesthesia was given to all patients and a pneumatic tourniquet was routinely used. In brief, through a 3 cm incision over the medial proximal tibia, semitendinosus (ST) and gracilis (Gr) tendons were harvested from the distal insertion. Tendons were quadrupled and whip stitched by No. 2 and No. 5 Ethibond sutures (Ethicon, Somerville, NJ). The diameters of the folded tendons were determined by using sizing cylinders with incremental size changes of 0.5 mm.The femoral sockets were created at about the 1:30 position (left knee), through the anteromedial portal. The tibial tunnel was created with an ACUFEX guide (Smith \& Nephew, Andover, MA). The diameters of the socket were created in the same manner as the diameter of the folded graft. At tibial site, grafts were fixed with bioscrews (BIORCI-HA, Smith \& Nephew) at 30 degrees of knee flexion. The screw and the tunnel sizes were the same. After completion of the procedure, a suction drain (Zimmer HEMOVAC, Warsaw, IN) was placed at the superior lateral aspect of the joint. Ten mL of TXA (100 mg/mL) (Daiichi Sankyo, Tokyo, Japan) was injected into the joint at the end of the operation and the drain was clamped for 2 h.

Clinical evaluations The volume of drainage was recorded 24 h after surgery. The grade of hemarthrosis, as previously described by Coupens et al.,was also documented at day 3 and week The range of knee motion and the IKDC functional score were evaluated 4 weeks post-surgery. The VAS was documented at postoperative day 3 and week 4.

Statistical analysis. All data are expressed as a mean and standard deviation (SD). The amount of drainage or functional scores between different groups were compared with an independent t test.

All statistical analyses were conducted using SPSS version 11.0 (SPSS Inc., Chicago,IL). Differences were considered significant when the p-value was \< 0.05.

02

Conditions studied

  • Anterior Cruciate Ligament Reconstruction

Browse trials for

Keywords

  • Anterior cruciate ligament reconstruction, knee, hemarthrosis, tranexamic acid
03

In context

Hemarthrosis

21 studies on the registry are indexed under Hemarthrosis; 5 are open to participants now.

This study's enrollment of 320 is above the median of 22 across 12 interventional studies indexed under Hemarthrosis.

Browse Hemarthrosis studies →

Lead sponsor

Taipei Veterans General Hospital, Taiwan is the lead sponsor of 338 studies on the registry; 74 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patient agreed to participate in this study, signed an document.
  2. patients receiving arthroscopic ACLR with autologous hamstring grafts

Exclusion criteria

Exclusion Criteria:

  1. previous knee procedures on the same side
  2. renal disorder or insufficiency
  3. abnormal coagulation profile
  4. refused to participate in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    Tranexamic Acid group

    Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.

    Drug: Tranexamic Acid Powder

  • Placebo comparator
    Control Group

    The control group patients only received ACLRs without TXA injections.

    Procedure: Post-anterior cruciate ligament reconstruction (ACLR)

Interventions

  • Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.

  • ProcedurePost-anterior cruciate ligament reconstruction (ACLR)

    Post-anterior cruciate ligament reconstruction (ACLR)

06

What researchers measure

Primary outcomes

  1. The volume of drainage

    hemoarthrosis

    Time frame: 24 hours after surgery.

Secondary outcomes

  1. The grade of hemarthrosis

    Grade I to IV.

    Time frame: At day 3 and week 4.

  2. The VAS was documented

    scale 0 to 10.

    Time frame: Postoperative day 3 and week 4.

  3. IKDC functional score

    Time frame: Evaluated 4 weeks post-surgery.

07

Study locations

1 site
  • Hsiao-Li
    Taipei, 11217, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03580018
Responsible party
Sponsor
First posted
Jul 9, 2018
Start date
Jun 1, 2017
Primary completion
May 31, 2018
Completion
May 31, 2018
Last update
Jul 12, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion